Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,177
archived clinical trials in
Orthopedic

Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated:  12/31/1969
Orthopaedic Specialty Institute (OSI)
1959
mi
from 43215
Orange, CA
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated: 12/31/1969
Orthopaedic Specialty Institute (OSI)
1959
mi
from 43215
Orange, CA
Click here to add this to my saved trials
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated:  12/31/1969
Neurosurgical Medical Clinic, Inc.
1948
mi
from 43215
San Diego, CA
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated: 12/31/1969
Neurosurgical Medical Clinic, Inc.
1948
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated:  12/31/1969
Spine Colorado
1348
mi
from 43215
Durango, CO
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated: 12/31/1969
Spine Colorado
1348
mi
from 43215
Durango, CO
Click here to add this to my saved trials
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated:  12/31/1969
Rezin Orthopedics and Sports Medicine
299
mi
from 43215
Morris, IL
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated: 12/31/1969
Rezin Orthopedics and Sports Medicine
299
mi
from 43215
Morris, IL
Click here to add this to my saved trials
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
624
mi
from 43215
Minneapolis, MN
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated:  12/31/1969
Jacobs Institute/UB Neurosurgery, Inc.
295
mi
from 43215
Amherst, NY
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated: 12/31/1969
Jacobs Institute/UB Neurosurgery, Inc.
295
mi
from 43215
Amherst, NY
Click here to add this to my saved trials
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated:  12/31/1969
Spine Center at Great Neck
492
mi
from 43215
Great Neck, NY
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated: 12/31/1969
Spine Center at Great Neck
492
mi
from 43215
Great Neck, NY
Click here to add this to my saved trials
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated:  12/31/1969
Carolina Neurosurgery & Spine Associates (CNSA)
349
mi
from 43215
Charlotte, NC
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated: 12/31/1969
Carolina Neurosurgery & Spine Associates (CNSA)
349
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated:  12/31/1969
Duke University
352
mi
from 43215
Durham, NC
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated: 12/31/1969
Duke University
352
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated:  12/31/1969
Carilion Clinic (Roanoke)
250
mi
from 43215
Roanoke, VA
Comprehensive Spinal Alignment Planning Study
A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used
Status: Enrolling
Updated: 12/31/1969
Carilion Clinic (Roanoke)
250
mi
from 43215
Roanoke, VA
Click here to add this to my saved trials
Single Shot vs 24hr vs 48hr Continuous Adductor Canal Block After TKA
A Randomized Study of Single Shot vs 24hr vs 48hr Continuous Adductor Canal Block for Postoperative Analgesia After Total Knee Arthroplasty
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Single Shot vs 24hr vs 48hr Continuous Adductor Canal Block After TKA
A Randomized Study of Single Shot vs 24hr vs 48hr Continuous Adductor Canal Block for Postoperative Analgesia After Total Knee Arthroplasty
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Dry Needling for Patients With Neck Pain
Dry Needling for Patients With Neck Pain: A Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Concord Hospital Rehabilitation Services
633
mi
from 43215
Concord, NH
Dry Needling for Patients With Neck Pain
Dry Needling for Patients With Neck Pain: A Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Concord Hospital Rehabilitation Services
633
mi
from 43215
Concord, NH
Click here to add this to my saved trials
Dry Needling for Patients With Neck Pain
Dry Needling for Patients With Neck Pain: A Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Franciscan, ST.Francis Health
mi
from 43215
Indianapolis, IN
Dry Needling for Patients With Neck Pain
Dry Needling for Patients With Neck Pain: A Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Franciscan, ST.Francis Health
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women
Status: Enrolling
Updated:  12/31/1969
Creighton University
683
mi
from 43215
Omaha, NE
Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women
Status: Enrolling
Updated: 12/31/1969
Creighton University
683
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
477
mi
from 43215
New York, NY
Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears
Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
643
mi
from 43215
Boston, MA
Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears
Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears
Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears
Status: Enrolling
Updated:  12/31/1969
Orthopaedic Institute
747
mi
from 43215
Sioux Falls, SD
Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears
Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears
Status: Enrolling
Updated: 12/31/1969
Orthopaedic Institute
747
mi
from 43215
Sioux Falls, SD
Click here to add this to my saved trials
Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears
Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears
Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain Patients
Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain Patients
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at Houston
990
mi
from 43215
Houston, TX
Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain Patients
Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain Patients
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at Houston
990
mi
from 43215
Houston, TX
Click here to add this to my saved trials
The Value of Home Chlorhexidine Pre-Surgical Wash Before Spine Surgery
The Value of Home Chlorhexidine Pre-Surgical Wash Before Spine Surgery
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
477
mi
from 43215
New York, NY
The Value of Home Chlorhexidine Pre-Surgical Wash Before Spine Surgery
The Value of Home Chlorhexidine Pre-Surgical Wash Before Spine Surgery
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
Continuous Blockade of the Brachial Plexus
Is There a Difference Between Posterior Approach Ultrasound-guided Continuous Interscalene Block (Upper Trunk Block) and Stimulator Guided Continuous Cervical Paravertebral Block (C6 Root Block)?
Status: Enrolling
Updated:  12/31/1969
UF Health
714
mi
from 43215
Gainesville, FL
Continuous Blockade of the Brachial Plexus
Is There a Difference Between Posterior Approach Ultrasound-guided Continuous Interscalene Block (Upper Trunk Block) and Stimulator Guided Continuous Cervical Paravertebral Block (C6 Root Block)?
Status: Enrolling
Updated: 12/31/1969
UF Health
714
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
Continuous Blockade of the Brachial Plexus
Is There a Difference Between Posterior Approach Ultrasound-guided Continuous Interscalene Block (Upper Trunk Block) and Stimulator Guided Continuous Cervical Paravertebral Block (C6 Root Block)?
Status: Enrolling
Updated:  12/31/1969
Florida Surgical Center
714
mi
from 43215
Gainesville, FL
Continuous Blockade of the Brachial Plexus
Is There a Difference Between Posterior Approach Ultrasound-guided Continuous Interscalene Block (Upper Trunk Block) and Stimulator Guided Continuous Cervical Paravertebral Block (C6 Root Block)?
Status: Enrolling
Updated: 12/31/1969
Florida Surgical Center
714
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1940
mi
from 43215
Upland, CA
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1940
mi
from 43215
Upland, CA
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis
1159
mi
from 43215
Denver, CO
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis
1159
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
204
mi
from 43215
Lansing, MI
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
204
mi
from 43215
Lansing, MI
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
848
mi
from 43215
Oklahoma City, OK
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
848
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis
2028
mi
from 43215
Portland, OR
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis
2028
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
495
mi
from 43215
Birmingham, AL
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
495
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1660
mi
from 43215
Phoenix, AZ
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1660
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1979
mi
from 43215
Beverly Hills, CA
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1979
mi
from 43215
Beverly Hills, CA
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1959
mi
from 43215
Fullerton, CA
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1959
mi
from 43215
Fullerton, CA
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
834
mi
from 43215
Brandon, FL
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
834
mi
from 43215
Brandon, FL
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
967
mi
from 43215
Fort Lauderdale, FL
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
967
mi
from 43215
Fort Lauderdale, FL
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
716
mi
from 43215
Gainesville, FL
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
716
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1507
mi
from 43215
Idaho Falls, ID
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1507
mi
from 43215
Idaho Falls, ID
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
278
mi
from 43215
Bowling Green, KY
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
278
mi
from 43215
Bowling Green, KY
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1493
mi
from 43215
Great Falls, MT
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1493
mi
from 43215
Great Falls, MT
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
513
mi
from 43215
Albany, NY
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
513
mi
from 43215
Albany, NY
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis
481
mi
from 43215
New York, NY
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
244
mi
from 43215
Duncansville, PA
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
244
mi
from 43215
Duncansville, PA
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
360
mi
from 43215
Greenville, SC
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
360
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1055
mi
from 43215
Leander, TX
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1055
mi
from 43215
Leander, TX
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
901
mi
from 43215
Mesquite, TX
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
901
mi
from 43215
Mesquite, TX
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1778
mi
from 43215
Spokane, WA
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1778
mi
from 43215
Spokane, WA
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
9248
mi
from 43215
Coffs Harbour,
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
9248
mi
from 43215
Coffs Harbour,
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
523
mi
from 43215
Potsdam, NY
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
523
mi
from 43215
Potsdam, NY
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
360
mi
from 43215
Charlotte, NC
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
360
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
322
mi
from 43215
Greensboro, NC
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
322
mi
from 43215
Greensboro, NC
Click here to add this to my saved trials
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
525
mi
from 43215
Charleston, SC
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
525
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
Predictive Models for Spine and Lower Extremity Injury After Discharge From Rehab
Development of Predictive Models for Lower Extremity, Lumbar, and Thoracic Injury After Discharge From Physical Rehabilitation
Status: Enrolling
Updated:  12/31/1969
Womack Army Medical Center
399
mi
from 43215
Fort Bragg, NC
Predictive Models for Spine and Lower Extremity Injury After Discharge From Rehab
Development of Predictive Models for Lower Extremity, Lumbar, and Thoracic Injury After Discharge From Physical Rehabilitation
Status: Enrolling
Updated: 12/31/1969
Womack Army Medical Center
399
mi
from 43215
Fort Bragg, NC
Click here to add this to my saved trials